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Background: Aim of this pilot study is to examine the effects of myo-inositol administration on ovarian response
and oocytes and embryos quality in non PolyCystic Ovary Syndrome (PCOS) patients undergoing multiple follicular
stimulation and in vitro insemination by conventional in vitro fertilization or by intracytoplasmic sperm injection.
Methods: One hundred non-PCOS women aged <40 years and with basal FSH <10 mUI/ml were down-regulated
with triptorelin acetate from the mid-luteal phase for 2 weeks, before starting the stimulation protocol for oocytes
recovery. All patients received rFSH, at a starting dose of 150 IU for 6 days. The dose was subsequently adjusted
according to individual response. Group B (n = 50) received myo-inositol and folic acid for 3 months before the
stimulation period and then during the stimulation itself. Group A (n-50) received only folic acid as additional
treatment in the 3 months before and through treatment.
Results: Total length of the stimulation was similar between the two groups. Nevertheless, total amount of
gonadotropins used to reach follicular maturation was found significantly lower in group B. In addition, the number
of oocytes retrieved was significantly reduced in the group pretreated with myo-inositol. Clinical pregnancy and
implantation rate were not significantly different in the two groups.
Conclusions: Our findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing
multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of
rFSH whilst maintaining clinical pregnancy rate. Further, a trend in favor of increased incidence of implantation in
the group pretreated with myo-inositol was apparent in this study. Further investigations are warranted to clarify
this pharmacological approach, and the benefit it may hold for patients.
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Myo-inositol is an isomer of a C6 sugar alcohol that
belongs to the vitamin B complex group [1]. Some
studies suggested that myo-inositol could play an im-
portant role in cellular morphogenesis and cytogenesis,
in the synthesis of lipids, in the creation of cell mem-
branes and in cell growth [2,3]. It is also a precursor of
phospholipids, which are responsible for the generation
of important intracellular signals in mammalian oocytes
and in the resumption of meiotic maturation [4-6]. The* Correspondence: franco.lisi01@gmail.com
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reproduction in any medium, provided the orpresence of myo-inositol in human body fluids and its
effect on the in vitro maturation of oocytes in rats have
led some authors to state that myo-inositol concentra-
tion in follicular fluid is significantly higher in follicles
containing good quality oocytes than in follicles contain-
ing poor quality oocytes [7].
Myo-inositol also regulates, via signal transduction
pathways, the secretion of some exocrine glands such as
pancreas and other organs, including the ovaries. In the
oocytes these intracellular pathways are involved in the
release of cortical granules, in the inhibition of poly-
spermy, in the completion of meiosis and in the activa-
tion of the cell cycle that subsequently results in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lisi et al. Reproductive Biology and Endocrinology 2012, 10:52 Page 2 of 7
http://www.rbej.com/content/10/1/52embryonic development [8]. It has been hypothesized
that intrafollicular myo-inositol concentration and oo-
cyte quality might be connected because inositol phos-
pholipids (of which myo-inositol is a precursor) are held
responsible for important intracellular signals essential
for oocyte development, and because myo-inositol itself
seems to improve oocytes in vitro maturation [8,9].
Recently, the role of myo-inositol has powerfully
emerged in the pathogenesis of polycystic ovary syn-
drome (PCOS), in particular linked with insulin resist-
ance. In fact, some of the actions of insulin are mediated
by putative inositol-containing phosphoglycan (IPG)
mediators, also known as putative insulin mediators or
second messengers. These mediators are generated by
hydrolysis of glycosylphosphatidylinositol lipids and/or
proteinated species located in the outer leaflet of the cell
membrane. Two different IPG have been identified: (i)
the D-chiro-IPG mediator, which activates pyruvate de-
hydrogenase phosphatase, and (ii) the MYO-IPG which
inhibits cyclic AMP-dependent protein kinase [10,11]. A
positive role of myo-inositol in insulin-resistant women
with PCOS could depend on defects in the insulin IPG-
mediated signaling pathway, that seems to be primarily
implicated in the pathogenesis of insulin resistance in
this clinical setting [12,13]. Accordingly, myo-inositol
has been classified as an insulin sensitizing agent and it
is commonly used in PCOS treatment [14-16]. By rescu-
ing the ovarian response to endogenous gonadotropins,
myo-inositol reduces hyperandrogenemia and re-
establishes menstrual cyclicity and ovulation, increasing
the chance of a spontaneous pregnancy [17,18]. Its use
in human is safe and only the highest dose (12 g/day)
induced mild gastrointestinal side effects such as nau-
sea, flatus and diarrhea [19].
The aim of this paper was to illustrate the progress re-
cently made in the use of myo-inositol in fertility treat-
ment and in particular to discuss its effects on ovarian
response and oocyte quality in non-PCOS patients
undergoing multiple follicular stimulations and in vitro
inseminations by conventional in vitro fertilization (IVF)
or by intracytoplasmic sperm injection (ICSI).
Methods
This prospective, randomized, open-label, multicenter
pilot study compared patients treated with 400 μg of
folic acid for the 3 months before and during rFSH ad-
ministration, following the long protocol (Group A,
n = 50) with patients that received a daily dose of
4,000 mg of myo-inositol into two administrations/day
in addition to 400 μg of folic acid for the 3 months be-
fore and during rFSH administration, following the long
protocol (Group B, n = 50). The trial adhered to the Hel-
sinki Declaration and the protocol was approved by the
Institutional Review Boards. All patients signed a writteninformed consent before entering the study. Inclusion
criteria were age< 40 years old and basal FSH level <10
mUI/ml. Patients presenting diagnostic criteria for
PCOS [14] or other concomitant endocrine and meta-
bolic diseases such as hypothyroidism, hyperthyroidism,
diabetes mellitus, androgen-secreting tumors, adrenal
hyperplasia, Cushing's syndrome, hyper-prolactinemia,
and all patients that underwent hormonal treatment in
the previous 3 months were excluded from the study.
Day 2 FSH, LH, 17β-estradiol (E2) and prolactin (PRL)
levels were measured in the previous 6 months. Patients'
BMI was between 18 and 28 and obese women (BMI
greater than 30 kg/m2) were excluded from the study:
Six patients of the initial cohort had a BMI greater than
30 kg/m2 (6/198; 3%). All patients began treatment dur-
ing a set period —January 2011 to January 2012 (“treat-
ment run”)— and were allocated to the treatment
groups using block randomization in a computer gener-
ated sequence: computer generated numbers 1-10000
into two columns – Column A was rFSH and folic acid
using the ‘even integers’; Column B was rFSH and folic
acid with addition of myo-inositol using odd integers
(Figure 1). Allocation to group A or group B was
decided on the day of first consultation and was not
known to doctors who performed the monitoring of fol-
licular development, changes in the amount of daily
International Units of rFSH, egg retrieval, in vitro
fertilization, embryo transfer and decided luteal support.
Patients enrolled in the study were recommended ICSI
or IVF after evaluation of their partner's semen. Patients
were down-regulated with triptorelin acetate (0.1 mg,
SC; Ferring, Italy) from the mid-luteal phase (day 21 of
the previous cycle) for 2 weeks, before starting the
stimulation protocol for oocyte recovery. In all patients,
ovarian suppression was confirmed by ultrasound scan
(absence of ovarian activity, ovarian cyst formation and
endometrial proliferation) and serum dosage of E2 levels
(≤40 pg/ml) before starting exogenous gonadotropins
administration. If ovarian suppression was not met,
down-regulation was extended for a further week. Group
A received folic acid at a dose of 400 μg per day for
3 months before and during treatment with gonadotro-
pins and received rFSH (Gonal F, Merck) at a starting
dose of 150 IU for 6 days. The dose was subsequently
adjusted according to individual response. Group B
received the same gonadotropins treatment and the
stimulation was preceded by the administration of
2,000 mg of myo-inositol twice a day and 400 μg per day
of folic acid for 3 months before starting follicular
stimulation and continued during the stimulation itself.
When conventional criteria for human chorionic go-
nadotropin (hCG) administration were met (at least
three follicles with a mean diameter >17 mm), recom-
binant human hCG, (250 μg SC; Ovitrelle, Merck
Figure 1 Flow chart showing the progress through the phases of the trial.
Lisi et al. Reproductive Biology and Endocrinology 2012, 10:52 Page 3 of 7
http://www.rbej.com/content/10/1/52Serono) was given (at least 24 hours after the last rFSH
administration) to induce final oocyte maturation.
Transvaginal oocyte retrieval was scheduled 35-37 hours
after the trigger injection. IVF or ICSI, depending on
semen parameters (data not shown), were then per-
formed. Oocytes retrieval, IVF or ICSI and embryos
transfer were carried out according to our usual clinical
practice [20]. Embryo quality was assessed morphologic-
ally, 2 days after fertilization using a grading system [21].
Grade 1 and 2 embryos have no or very few fragments
in the cytoplasm with equal size blastomeres and there-
fore are considered the best embryos. Grade 3 and 4
embryos have significant or severe fragmentation; little
cytoplasmic fragmentation with blastomeres of dis-
tinctively unequal size [21]. The luteal phase was sup-
ported by 800 mg/day transvaginal-micronized
progesterone (Progeffik, Effik Italia S.p.A, Milan, Italy)
and treatment was continued until either a serum preg-
nancy test result was negative or an embryonic heartbeat was sonographically confirmed. Serum hCG level
was measured 14 days after oocyte retrieval. A slight
and transitory increase in β-hCG level was defined as a
biochemical pregnancy. A gestational sac with fetal
heartbeat movement seen on transvaginal ultrasound
scan 4 weeks after embryo transfer, confirmed clinical
pregnancy.
Statistical analysis
The number of treated patients and controls was com-
puted with respect to a two-tailed Student t test for in-
dependent groups, considering a (i) difference in
gonadotropins dosage required to reach follicular matur-
ation to be detected between patients and controls
|δ| ≥ 15%, (ii) type I error probability α= 0.05 and power
1− β= 0.72; this resulted in n = 50 for group. Sample size
calculation was performed using the software nQuery
Advisor, version 5.0 (Statistical Solutions, Saugus, Mas-
sachusetts). Analysis was performed according to an
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ent samples was used to evaluate statistical differences
between groups for continuous variables. Comparisons
between proportions were conducted using the Pearson’s
chi-square test.
Data are presented as mean± SD. Probability values
< 0.05 were regarded as statistically significant. All cal-
culations were made with the computer programme
STATISTICA 7 (StatSoft, Tulsa, OK, USA).
Results and discussion
Patients' age was similar in the two groups as well as
BMI, FSH, LH and E2 basal levels. After the down-
regulation treatment, LH level was significantly higher
in patients pre-treated with myo-inositol [Group A:
1.6 ± 0.9 mUI/ml; Group B: 2.7 ± 1.1mUI/ml, p< 0.01],
while basal FSH and basal E2 were similar (Table 1).
The total length of the stimulation was similar between
the two groups [Group A: 11.7 ± 1.8 days; Group B:
11.8 ± 1.5 days; p = 0.64]. The total amount of gonado-
tropins used to reach follicular maturation was signifi-
cantly reduced in group B [Group A: 2,479 ± 979 IU;
Group B: 2,084 ± 648 IU; p <0.05]. E2 peak level on the
day of hCG administration was found to be lower, but
not statistically significant, in group A [Group A:
1.312 ± 629; Group B 1.516 ± 942 pg/ml, p = 0.12] and
the number of oocytes per patient retrieved resultedTable 1 Baseline and stimulation characteristics of
patients in group without (Group A) and with (Group B)
pretreatment with Myo-inositol
No myo-inositol Yes myo-inositol p
Group A Group B
N=50 N=50
No. of patients 50 50
Age (year) 33.3 ± 2.8 34.4 ± 3.4 0.09
BMI 22.9 ± 3.3 22.7 ± 2.6 0.88
FSH (mIU/ml), basal 7.3 ± 1.5 7.2 ± 2 0.35
LH (mIU/ml), basal 4.7 ± 2 4.9 ± 2 0.87
17β-estradiol (E2) (pg/ml), 47.2 ± 17.8 43.6 ± 12.7 0.20
basal
FSH (mIU/ml), down 4.7 ± 1.5 4.6 ± 2.2 0.87
regulation
LH (mIU/ml), down 1.6 ± 0.9 2.7 ± 1.1 <0.01
regulation
17β-estradiol (E2) (pg/ml), 26.4 ± 20 24.4 ± 14.5 0.31
down regulation
rFSH treatment days 11.7 ± 1.8 11.8 ± 1.5 0.64
Total rFSH dose (IU) 2,479± 979 2,084 ± 648 <0.05
E2 (pg/ml), day of hCG 1,312± 629 1,516 ± 640 0.12
Total length of stimulation 11.7 ±1.8 11.8 ± 1.5 0.64significantly higher in group A [Group A: 7.6 ± 3.8 per
patient (Tot. 380); Group B: 5,9 ± 2,4 oocytes per patient
(Tot. 297), p< 0.01] (Table 2). In addition the number
(mean ± SD) of Metaphase II eggs, number of insemi-
nated eggs, number of 2PN oocytes and number of
embryos were significantly higher in group A compared
with group B (Table 2). Fertilization rate, cleavage rate,
percentage of grade I and II embryos, number of
patients receiving embryos and number of embryos
received were similar in both groups (Table 2).
The number of clinical pregnancies was also similar
[Group A: 12/47 (25,5%); Group B: 14/47 (29,8%),
p = 0.52]. Finally, even the implantation rate (number of
gestational sac with fetal heartbeat/total number of
embryos transferred) was similar in the two groups of
patients [Group A: 13,3%; Group B: 18,7%, p = 0.08]
(Table 2).
PCOS affects 5%-10% of women in reproductive age,
and is the most common cause of infertility due to ano-
vulation. Insulin resistance is common in PCOS women,
regardless of their body mass index. The importance of
insulin resistance in PCOS is also suggested by the fact
that insulin-sensitizing compounds have been proposed
as putative treatments to solve hyperinsulinemia-
induced dysfunction of ovarian response to endogenous
gonadotropins. Rescuing ovarian response to endogen-
ous gonadotropins reduces hyperandrogenemia and re-
establishes menstrual cyclicity and ovulation, increasing
the chance of a spontaneous pregnancy. Among insulin-
sensitizing compounds, myo-inositol has been shown to
be able to restore spontaneous ovarian activity, and con-
sequently fertility, in most patients with PCOS
[18,22,23]. Myo-inositol may be a useful tool in the
treatment of PCOS patients undergoing ovulation induc-
tion for its insulin-sensitizing activity. Myo-inositol has
also been proposed as an adjuvant in multiple follicular
stimulation for IVF in patients known to suffer from
PCOS : the pretreatment with myo-inositol and folic
acid was shown to reduce germinal vesicles and degener-
ated oocytes at ovum pick-up, without compromising
the total number of retrieved oocytes [8,24].
However, the intent of this study was to assess the role
of myo-inositol in cellular morphogenesis and cytogen-
esis. At present not many data are available regarding
the action and effects of myo-inositol in non-PCOS
women in childbearing age, in spontaneous ovulation
and in stimulation cycles. Increasing evidence supports
the physiological and therapeutic role of myo-inositol in
human reproduction and in particularly in oogenesis
playing an important role in cell morphogenesis and
cytogenesis, lipid synthesis, structure of cell membranes
and cell growth [2,3]. Some studies have shown that
myo-inositol is incorporated into phosphoinositides and
inositol phosphates in rabbit embryos [25] and can
Table 2 Study outcomes in the two treatment groups
No myo-inositol Yes myo-inositol p
Group A Group B
N=50 N=50
No. oocytes retrieved/patient 7.6 ± 3.8 5.9 ± 2.4 <0.01
Mean± SD
No. metaphase II/patient 6.3 ± 2.9 4.8 ± 2.2 <0.05
Mean± SD
No. inseminated eggs/patient 6 ± 2.7 4.8 ± 2.2 (240) <0.05
Mean± SD
No. 2PN oocytes/patient 4.3 ± 2.3 3.3 ± 1.8/163 <0.01
Mean± SD
Fertilization rate (2PN/inseminated oocytes) 70.8 ± 20.4 68.4 ± 19.2 0.7
(%) ± SD
No. Embryos/patient 3.58 ± 2.1 2.5 ± 1 .1 <0.001
Mean± SD
Cleavage rate (embryos/2PN oocytes) 82.2 ± 29.9 84.5 ± 28.7 0.7
(%) ± SD
No. embryos Grade I and II : number 173 (96.6%) 117 (93.6%) 0.2
and percentage of total
No. of patients receiving 47 (94%) 47 (94%) 1
embryos (%)
No. of embryos transferred per 2.4 ± 1 2.2 ± 0.8 0.39
starting patients Mean± SD
No. Clinical pregnancies 12/47 (25.5%) 14/47 (29.8%) 0.52
No. of fetal hearts 16 (13.3%) 21 (18.7%) 0.08
(implantation rate)
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culture with medium supplemented with myo-inositol
[26]. Results from these studies support the notion that
myo-inositol serves as a precursor for the synthesis of
phosphoinositides. This constitutes the phosphatidylino-
sitol (PtdIns) signal transduction system known to be
involved in the regulation of diverse cellular functions
including cell proliferation [27]. During ovulation induc-
tion for an IVF cycle two important parameters need to
be monitored: E2 concentration and follicles size/num-
ber. An increase in these two factors has been correlated
with a higher level of myo-inositol in the follicular fluid
[7]. In 1992 Chiu and Tam [28] demonstrated that
serum myo-inositol could be a trophic factor responsible
for promoting in vitro development of preimplantation
embryos.
Myo-inositol is an important element of the follic-
ular microenvironment that plays a crucial role in oo-
cyte maturation. In fact, in Assisted Reproduction,
supplementation of myo-inositol is positively related to
oocyte meiotic progression of germinal vesicles in rats,increasing the intracellular calcium oscillations [4,28,29].
In patients treated with exogenous gonadotropins plus
myo-inositol there was a significant reduction in the
number of oocytes retrieved and in the number of folli-
cles recruited. For this reason we can assume that this
approach could be adopted to reduce the risk of hyper-
stimulation. Overall, these results provide a further sup-
port to the hypothesis that myo-inositol may promote
the meiotic maturation acting on intracellular signal
transduction in calcium pathways [29-31]. A complete
meiotic maturation requires intracellular changes asso-
ciated with both nuclear and cytoplasmic components
[30]. At present, although most of the morphological
and biochemical changes during maturation are well
documented, a complete identification of specific factors
that directs these changes is lacking [32]. The fertiliz-
ability of oocytes, their ability to initiate embryo split-
ting, and the subsequent preimplantation development
are now considered a fundamental part of a proper as-
sessment of cytoplasmic maturation [33]. It is interest-
ing to highlight how LH level during down regulation
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[Group A: 1.6 ± 0,9 mIU/ml; Group B: 2.7 ± 1.1 mIU/ml,
p< 0.01]. Although the meaning of this finding is not
clear, we can speculate that the increased rate of circu-
lating LH is responsible for the higher level of E2 on the
day of HCG administration (although not significant in
our group of patients) and for the lower number of folli-
cles recruited, suggesting that it may be a cofactor for
better oocytes and embryos quality [34].
Conclusion
The addition of myo-inositol seems to reduce gonado-
tropin dosage and the number of MII oocytes retrieved
in non-PCOS patients pretreated with myo-inositol for
3 months. However, this study is underpowered to
evaluate IVF outcomes like implantation and clinical
pregnancy with the mechanism of improved oocyte
competence. Therefore a subsequent adequately pow-
ered RCT is underway.
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